Clinical trial
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS…
NCT01781572 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT01781572 |
|---|---|
| Title | A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma |
| Official title | A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Locally Advanced or Metastatic NRAS Mutant Melanoma |
| Intervention type | Drug |
| Interventions | LEE011, MEK162 |
| Enrollment | 102 |
| Start date | Jun 1, 2013 |
| Primary completion | Jan 15, 2018 |
| Completion | Feb 20, 2018 |
| First posted | Feb 1, 2013 |
| Last update posted | Dec 7, 2020 |
| Countries | Australia, Germany, Italy, Netherlands, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: